Brenus Pharma is a pioneering biotechnology company focused on the discovery and development of immune therapies for cancer. The company operates in the oncology sector, specifically targeting solid tumors, both rare and frequent. Brenus Pharma's core product is its scalable discovery platform that generates allogeneic cell-based vaccines, which are designed to facilitate the scale-up and market access of immunotherapy for cancer patients. The company collaborates with top experts in immuno-oncology and vaccines, and shares data with academic institutions to advance its research and development efforts.

Brenus Pharma's business model revolves around the development and commercialization of its proprietary immunotherapy solutions. The company generates revenue through grants, such as the one from BPI French Public Investment Bank, and through partnerships with Contract Research Organizations (CROs) like Transcure, which specializes in humanized mice models for cancer research. Brenus Pharma is currently preparing for regulatory approvals and clinical trials to expedite the development of its lead candidate in metastatic colorectal cancer (mCRC).

The company serves a diverse clientele, including cancer patients, healthcare providers, and research institutions. By focusing on high unmet medical needs in oncology, Brenus Pharma aims to provide innovative solutions that improve patient outcomes and advance the field of cancer immunotherapy.

Keywords: immunotherapy, allogeneic cell vaccines, oncology, solid tumors, scalable platform, cancer research, regulatory approvals, clinical trials, metastatic colorectal cancer, immuno-oncology.